Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

  1. Home
  2. PAAB Q&A
  3. FYI post-approval change/preclearance exemption/what requires review/PAAB scope
  4. 432 - With reference to PAAB Code section 6.6 (vii), what is the difference between class and category? Would an unbranded patient piece that mentions "treatment" without any specifics be exempt from PAAB preclearance? For further context, the disease state that the piece focuses on can be managed in various ways, including watch and wait.
PAAB Notice
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

432 - With reference to PAAB Code section 6.6 (vii), what is the difference between class and category? Would an unbranded patient piece that mentions "treatment" without any specifics be exempt from PAAB preclearance? For further context, the disease state that the piece focuses on can be managed in various ways, including watch and wait.

Scheduled Pinned Locked Moved FYI post-approval change/preclearance exemption/what requires review/PAAB scope
1 Posts 1 Posters 287 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • Jennifer CarrollJ Offline
    Jennifer CarrollJ Offline
    Jennifer Carroll
    wrote on last edited by
    #1

    "Class" refers to pharmacological classification (e.g. ACEI, Beta-Blocker, Calcium Channel Blocker). "Category" refers to a higher level in the hierarchy (e.g. "antihypertensive treatment", "blood pressure meds", "drug treatment for blood pressure". I say "higher level" simply in the sense that there can be more than one class in a category. You’ve touched on an interesting property relating to the term "treatment". Although it often refers to drug treatment (especially in the context of APS generated by pharmaceutical companies), it is possible that it refers solely to lifestyle adjustments, medical devices…etc (i.e. completely exclusive of drug therapy). Context is important in cutting through that ambiguity. Generally, the executions I’ve seen don’t stop at the fact that management includes watch and wait. They usually go on to say "…and drugs… to help reduce the risks of heart attacks and death and help improve quality of life". That may or may not be an infraction for the therapeutic area at hand. That’s why the content would be reviewable under section 7.5 of the PAAB code (i.e. so you can find out and adjust accordingly as needed). The point is to ensure that the manner in which medications (even on the conceptual level) are represented vis-à-vis the disease is accurate, balanced, and evidence based.

    1 Reply Last reply
    0
    Reply
    • Reply as topic
    Log in to reply
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes


    • Login

    • Don't have an account? Register

    • Login or register to search.
    • First post
      Last post
    0
    • Categories
    • Recent
    • Tags
    • Popular
    • Users
    • Groups